The Growing Wave of Biotech IPOs in China

As the biotechnology industry becomes more global, companies must evaluate and adopt various cross-border strategic models to drive capital formation and growth.
Reforms within China affecting the biomedical industry, such as the accelerated review and approval of drugs, and the expansion of the reimbursement scheme have provided a catalyst for transformation and innovation throughout Asia.
One year ago, the Hong Kong Exchange (HKEX) began to allow pre-revenue biotechnology companies to list &nd